StarpharmaのBeta
StarpharmaのBetaは何ですか。
Starpharma Holdings LimitedのBetaは1.12です。
Betaの定義は何ですか。
BETAは、株式が市場全体よりも多かれ少なかれ揮発性であるかどうかを示します。 1未満のベータは株式が市場よりも揮発性が低いことを示し、1より大きいベータは株式がより揮発性であることを示します。ボラティリティは、平均値周辺の価格の変動として測定されます。
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
ASXのセクタHealth CareにおけるBetaの企業と比べるStarpharma
Starpharmaは何をしますか。
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Starpharmaと類似のbeta
- BroadcomのBetaは1.12です。
- WestRockのBetaは1.12です。
- Navient CorpのBetaは1.12です。
- U.S. Well ServicesのBetaは1.12です。
- Zephyr plcのBetaは1.12です。
- United Parcel ServiceのBetaは1.12です。
- StarpharmaのBetaは1.12です。
- Howmet Aerospace IncのBetaは1.12です。
- Excellon ResourcesのBetaは1.12です。
- Gyscoal AlloysのBetaは1.12です。
- RattanIndia InfrastructureのBetaは1.12です。
- RattanIndia InfrastructureのBetaは1.12です。
- LionのBetaは1.12です。